Carmofur
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA) . Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) [1][2][3].
Product Specifications
CAS Number
61422-45-5
Product Name Alternative
HCFU
UNSPSC
12352005
Hazard Statement
H301, H361
Target
Ceramidase; FAAH; Glutathione Peroxidase; Nucleoside Antimetabolite/Analog; SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/carmofur.html
Purity
99.95
Solubility
DMSO : 83.33 mg/mL (ultrasonic)
Smiles
O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC
Molecular Formula
C11H16FN3O3
Molecular Weight
257.26
Precautions
H301, H361
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Pyrococcus Fruriosus Deoxyuridine Triphosphatase
